NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Subscribe To Our Newsletter & Stay Updated
